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ABSTRACT 
Nebivolol (NEB) is an antihypertensive drug with poor oral bioavailability (12%) in humans due to extensive first pass hepatic 
metabolism. Present work is an attempt to improve oral bioavailability of nebivolol by incorporating it with biodegradable polymer 
chitosan and preparing its nanoparticles. The results indicated stable nanoperticles with the value of ZP to be +36.4 mV ± 2 mV, the 
small particle size of 79.23 ± 45 nm and high entrapment efficiency of 72.56%. The in vitro release study revealed sustained release 
of drug for 72 h with 71.24% cumulative drug release. The promising results from the study revealed the applicability of chitosan in 
the formulation of NEB loaded CNPs. 
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INTRODUCTION 
High blood pressure is estimated to cause 7.1 million 
deaths, about 13 percent of the global fatality total. It is 
believed this number will grow to approximately 11 
million by the year 2020. Heart disease is the leading 
cause of death worldwide each year. Cardiovascular 
disease is also the leading cause of death in India, 
accounting for over 4 million deaths each year. 
Hypertension is the leading risk factor for cardiovascular 
and renal disease, increasing the risk of myocardial 
infarction, stroke, congestive heart failure, ruptured 
aortic aneurysm, and renal disease. It is clearly 
understandable that a more rational approach to 
diagnosing and treating high blood pressure could have a 
substantial impact on population morbidity and 
mortality.
1
 
Oral administration of drugs is considered to be the most 
natural, uncomplicated, convenient and safe method. 
Since nearly one third of drugs are poorly water soluble, 
oral bioavailability of those drugs could be issue.
2
Drug 
solubility has a significant impact on bioavailability, 
therefore selecting and optimising an appropriate drug 
formulation is imperative to the success of the program; 
moreover there is currently a very high prevalence of 
low solubility drugs in development (70%)
 3
. Although 
solubility can be estimated through in vitro dissolution 
studies, and performance predicted through insilico 
modelling tools, the full impact can only be truly 
assessed once the drug has been administered to humans 
in a clinical trial
4
. Although formulation technologies 
are available that can help to reduce the impact of 
solubility challenges on bioavailability. Formulation 
approaches are broadly classified into two categories: 
drug substance modification and drug product 
(formulation) modification. In modifying the drug 
substance, the chemical form of the drug can be changed 
by generating a new polymorph or salt, and the physical 
form of the drug can be amended by reducing the 
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particle size or crystallinity. In each case, the dissolution 
rate and/or solubility of the drug may be enhanced
5, 6
. 
However, if these approaches prove unsuccessful, 
formulations can also be designed to improve solubility. 
Examples of these include cyclodextrin complexes, 
lipid-based formulations, suspensions, nanoparticles, 
nanosuspensions, and spray dried dispersions; all of 
which contain solubility-enhancing excipients 
appropriate for the particular drug substance. Once the 
drug substance or formulations have been modified, it 
must be evaluated to see whether the solubility has 
improved
7
.  
Nebivolol hydrochloride is a BCS class II drug and 
receptor blocker with nitric oxide-potentiating 
vasodilator effect. It is used in treatment of hypertension 
and is highly cardioselective. It lowers blood pressure by 
reducing peripheral vascular resistance and significantly 
increases stroke volume with preservation of cardiac 
output. Nebivolol has reduced typical beta-blocker 
related side effects such as fatigue, clinical depression, 
bradycardia, and impotence. Nebivolol has half-life of 
about 10 hrs. It reaches mean peak plasma concentration 
approximately in 1.5 to 4 h post oral administrations 
8
. 
In such cases it is very essential to enhance onset of 
action of a drug. Therefore, in this work the goal has 
been set to design, development and characterization of 
a mucoadhesive controlled-release nanoperticles of 
Nebivolol using biodegradable polymer Chitosan.  
MATERIALS AND METHODS  
Materials  
Chitosan (CS) was obtained as gift sample from Central 
Institute of Fisheries Technology (Cochin, India). 
Sodium tripolyphosphate (TPP) was procured from Loba 
Chemie Pvt. Ltd. (Mumbai, India). Nebivolol (NEB) 
was obtained as a gift sample from Lupin Ltd. 
(Pitahmpur, Indore, India). All other chemicals and 
reagents were of analytical grade. 
Preparation of NPs  
The NB-loaded NPs were fabricated according to the 
procedure reported by (Ajun et al. 2009, Patel et al. 
2013)
9
. Briefly, Chitosan solutions of different 
concentrations were prepared by dissolving chitosan in 
1% aqueous acetic acid solution. Tween 80 (2% v/v) 
was added as a surfactant to it under constant stirring at 
room temperature. Subsequently, drug (2.5%) was 
dissolved in dichloromethane (2.5 mL), and then this oil 
phase was added dropwise to the aqueous phase. This 
addition was accompanied by continuous stirring for 5 
minutes at different speeds using high speed 
homogenizer. Finally, 10ml TPP solution of different 
concentration was added drop wise into o/w emulsion to 
induce cross-linking of the particles under magnetic 
stirring at 500 rpm. The stirring was continued to ensure 
complete evaporation of dichloromethane, it was kept 
overnight at 40°C. Nanoparticles were collected by 
centrifugation at 15,000 rpm for 25 minutes at 20°C 
using cooling centrifuge. The supernatant was subjected 
for the determination of presence of free Nebivolol by 
UV spectrophotometer (UV 1700, Shimadzu, Japan). 
Characterization of NPs  
Transmission electron microscopy (TEM) 
The morphology of nanoparticles was observed under 
transmission electron microscopy (Morgagni 268D TEM 
instrument, AIIMS, New Delhi).  
Scanning electron microscopy (SEM) 
The particles were characterized by Scanning Electron 
Microscopy (SEM, Jeol JSM-6360LV) at a voltage of 
20 kV after prior coating with gold/palladium under 
vacuum by sputtering using a BAL-TEC apparatus. 
Drug-excipient compatibility studies by differential 
scanning calorimeter (DSC)  
The nanoparticles and drug powder were subjected to 
previously calibrated differential scanning calorimeter 
(DSC-60, Shimadzu Corporation, Japan). The sample 
was sealed hermetically in an aluminum pan and 
subjected to nitrogen gas at a flow rate of 50 ml/min. 
The thermograms were obtained at scanning temperature 
range of 50-250°C at a heating rate of 10°C/min. DSC 
thermograms were recorded for CS, NEB and NEB-CS 
NPs. 
Measurement of particle size, polydispersity index 
(PDI), and zeta potential (ZP) of NPs  
Particle size, PDI and ZP of nanoparticles were 
determined through Dynamic light scattering (DLS) 
analysis with Malvern Zetasizer Nano S (Malvern, UK). 
The analysis was performed in triplicate at a temperature 
of   25 
 
C.  
Determination of entrapment efficiency  
The entrapment efficiency of the nanoparticulate 
formulation was determined in triplicate using ultra-
violet spectrophotometer.  The nanoparticles were 
separated from the aqueous medium (containing 
unentrapped NEB) by centrifugation at 25000 rpm for 
30 min (REMI CPR-24 Plus, Remi Elektrotechnick, 
India). The supernatant was diluted with an appropriate 
amount of 0.1 N HCl and analyzed for the amount of 
unentrapped drug by UV-Visible spectrophotometer 
(Shimadzu 1700, Japan) at 285 nm.  
The percentage drug encapsulated was determined by 
following the formula: 
Entrapment efficiency (%) = 
                –               
               
× 100 
 
In vitro drug release studies  
The in-vitro drug release of nanoparticles was studied by 
using dialysis membrane (Himedia, India) with a pore 
size of 2.4nm and molecular weight cut-off between 
12,000–14,000 in phosphate buffer saline (PBS) pH 7.4 
at 37 ± 2˚C. The amount of drug released was analyzed 
spectrophotometrically at 285 nm for NEB.  
Accelerated stability studies  
Nebivolol loaded nanoparticles were subjected to a 
stability testing for three months as per International 
Conference on Harmonisation (ICH) Q1A guidelines. 
Sharma et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2018; 8(2):118-122                 
ISSN: 2250-1177                                                                            [120]                                                                              CODEN (USA): JDDTAO 
Freshly prepared nanoparticles were transferred to 5 ml 
glass vials sealed with plastic caps and were kept in 
stability chamber (Remi SC-12 Plus, Remi Instruments. 
Ltd. Mumbai, India) maintained at 25 ± 2∘C/60 ± 5%RH 
for a period of total 3 months.  The formulations were 
monitored for changes in particle size, zeta potential and 
entrapment efficiency. 
 
RESULTS AND DISCUSSION  
Particle size analysis by transmission electron 
microscopy (TEM) 
The structural morphology of nanoparticles was 
examined by TEM. TEM image showed that the 
optimized formulation is nearly spherical in shape and a 
smooth surface distributed throughout the sample 
(Figure 1).  
 
 
Figure 1: TEM image of the nanoparticles 
 
Particle Morphology analysis by Scanning electron 
microscopy (SEM) 
The SEM images of the nanoparticles showed spherical, 
smooth and homogeneous particles (Figure 2). 
 
Figure 2: SEM image of the nanoparticles 
Drug-excipients compatibility studies by DSC 
The DSC curves of CS, NEB and drug loaded CS NPs 
were obtained. There is no detectable endotherm if the 
drug is present in a molecular dispersion or solid 
solution state in the polymeric nanoparticles
10
. It was 
seen that the DSC thermograms of drug loaded CS NPs 
showed a broad endothermic peak at 101.66°C which 
was due to the glass transition temperature of chitosan. 
However, the melting peak of drug was absent in the 
thermogram of NPs indicating that NEB was 
incorporated in amorphous form in the CS matrix in the 
NPs. 
Particle size, poly dispersity index (PDI) and zeta 
potential of nanoparticles 
The average particle size of the nanoparticles was found 
to be 79.23 ± 45 nm(Figure 3). Particle size along with 
zeta potential (ζ) is the critical factor that affects the 
biological performance of chitosan nanoparticles. The 
zeta potential of NB-CS-NPs were found to be + 
36.4mV ± 2mV (Figure 4), which indicate the physical 
stability of the formulation. The zeta potential also tends 
to affect particle stability and mucoadhesivity.  
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Figure 3: Particle size of the nanoparticles  
 
Figure 4: Zeta potential of nanoparticles 
 
Entrapment efficiency 
The entrapment efficiency acts as an important factor 
influencing the drug release, as well as the overall 
efficacy of the formulation.  All the formulations were 
analyzed for entrapment efficiency by using UV-Visible 
spectrophotometer (Shimadzu 1700, Japan) at 285 nm 
and. The entrapment efficiency of the nanoparticles was 
found to be 72.56%. 
In vitro drug release 
The In vitro drug release studies were carried out for 
NEB -CS NPs and marketed formulation in PBS 7.4 at 
37 ˚C± 2˚C . The drug release profile of NB-CS-NPs 
showed biphasic release pattern with an initial burst 
release in the first 2 h followed by a controlled release 
over a period of 72 hours and cumulative percentage of 
drug released was obtained to be 71.24 %.  (Figure 5) 
Accelerated stability studies 
Stability studies were conducted in triplicate for 
optimized formulation which showed slight variations in 
particle size, zeta potential, and drug entrapment during 
3 months of storage. The obtained results indicated no 
significant change in the particle size, zeta potential, and 
drug entrapment during 3months of storage that ensured 
the stability of nanoparticles. 
 
Figure 5: Cumulative percentage of drug released from 
nanoparticles 
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CONCLUSION 
The major challenge in the formulation development is 
the poor aqueous solubility of the new chemical entity or 
existing drug molecules. The formulation of these 
molecules by the application of conventional approaches 
is difficult and associated with several pharmacological 
or therapeutical performance issues. The nanoparticles 
provide a promising approach for enhancing solubility 
and oral bioavailability of water insoluble drugs.  In 
conclusion, formulation of chitosan nanoparticles could 
be an effective strategy for enhancing oral 
bioavailability of nebivolol and other lipophilic drugs 
upon further in vivo pharmacokinetics and 
pharmacodynamics studies.  
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